THURSDAY, June 29, 2023 (HealthDay News) Animal research is pointing toward a new way to prevent HIV infection: a refillable implant that continuously delivers antiretroviral medications for up to
THURSDAY, June 29, 2023 (HealthDay News) Animal research is pointing toward a new way to prevent HIV infection: a refillable implant that continuously delivers antiretroviral medications for up to
The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2) in 8 patients with mild-to-moderate AD. The study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.
Coya’s investigational low-dose interleukin-2 (ld IL-2) for subcutaneous administration has been designed to enhance in vivo the anti-inflammatory function of regulatory T cells (Tregs).
Treg dysfunction has been associated with increased neuroinflammation, which is observed in AD and other neurodegenerative diseases, and may contribute to disease severity and progression.
Coya Therapeutics, Inc.: Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Alzheimer's Association International Conference (AAIC) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.